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Abstract
Background: Semaphorin 7A (Sema7A) is expressed by several different classes of lymphoid and myeloid cells and
is a potent immunomodulator. We examined the role of Sema7A in modulating cellular immune responses and to
provide experimental data validating the therapeutic potential of Sema7A in rheumatoid arthritis (RA).
Methods: Soluble Sema7A (sSema7A) levels in the serum and synovial fluid from patients with RA or osteoarthritis,
as well as cytokine secretions, were analyzed with an enzyme-linked immunosorbent assay. The cell surface levels
and transcripts of Sema7A were evaluated in T cells and monocytes from patients with RA. The effect of Sema7A
on the functions of primary T cells isolated from the peripheral blood of healthy donors was observed. Detection of
the activation of the signal mediator focal adhesion kinase was performed by Western blotting. Shedding of
sSema7A was evaluated in monocytes. The introduction of anti-Sema7A antibody to mice with collagen-induced
arthritis (CIA) was observed in vivo.
Results: Upregulation of sSema7A levels in both the serum and synovial fluid of patients with RA was correlated
with disease activity markers. sSema7A markedly increased Th1/Th17 cytokine secretion and induced evident
upregulation of T-bet and retinoic acid receptor-related orphan nuclear receptor γt levels in T cells. Cell surface
Sema7A was cleaved by a disintegrin and metalloprotease 17 (ADAM17) in monocytes. Interleukin-6 and tumor
necrosis factor-α stimulated ADAM17 secretion in synovial macrophages. Blocking of β1-integrin abrogated the
Sema7A-mediated cytokine secretion. Treatment with an anti-Sema7A antibody significantly attenuated CIA.
Conclusions: These findings indicate that Sema7A as a potent activator of T cells and monocytes in the immune
response contributes to the inflammation and progression of RA, suggesting its therapeutic potential in the
treatment of RA.
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Background
Rheumatoid arthritis (RA) is an autoimmune and systemic
inflammatory disorder characterized by synovial inflam-
mation, destruction of cartilage and bone, and systemic
manifestations [1, 2]. RA synovial inflammation evokes
arthritis symptoms and causes articular bone and cartilage
destruction. In RA joints, the immune cells infiltrating the
synovium include T cells, macrophages, B cells, and den-
dritic cells [3]. Activated synovial T cells and macrophages
secrete various types of proinflammatory cytokines, in-
cluding interleukin-6 (IL-6), tumor necrosis factor-α
(TNF-α), and IL-17 [4, 5]. Among the different inflamma-
tory cells, T-helper cell type 1 (Th1) cells, as potent cyto-
kine producers, are considered to be crucial effector cells in
RA [6]. Recently, considerable evidence has been presented,
both in humans and in mice, for the importance of Th 17
cells as the main source of IL-17 in the development and
progression of autoimmune diseases. However, the role of
inflammatory cells in RA has remained elusive.
Semaphorins comprise a large family of transmembrane
proteins and secreted proteins that have been described as
axon guidance molecules during neuronal development.
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They are divided into eight classes based on sequence simi-
larities and distinct structural features [7, 8]. Of the eight
classes of semaphorins, classes 1 and 2 semaphorins are
found in invertebrates, whereas classes 3–7 semaphorins
are found in vertebrates and class 8 semaphorins are viral.
Plexin-semaphorin-integrin domains, immunoglobulin-like
domains, PDZ domains, and/or thrombospondin domains
have also been shown to be part of the semaphorin protein
structure. Semaphorins were initially described for their
role in axon guidance during neurogenesis [9]. It has since
been found that semaphorins branch beyond the nervous
system to cover an ample overlap of molecular repertoires.
Semaphorins are also involved in physiological processes
such as organogenesis, immune cell regulation, and vascu-
lar growth [10].
Semaphorin 7A (Sema7A) is the only class 7 semaphorin,
also known as CD108, with a membrane-associated, glyco-
sylphosphatidylinositol (GPI)-linked semaphorin protein
that contains arginine-glycine-aspartate [11], a well-
conserved, integrin-binding motif, in its Sema domain.
Sema7A has an immune function in both the innate and
adaptive immune systems [12]. Previous studies have
shown that semaphorins have important roles in immuno-
logic disorders, such as multiple sclerosis, contact hyper-
sensitivity, experimental autoimmune encephalomyelitis,
granulomatosis with polyangiitis (Wegener’s), and RA [13,
14]. Recently, on one hand, several studies have shown that
Sema7A is a potent stimulator of monocytes inducing the
production of proinflammatory cytokines [15]. On the
other hand, Sema7A has been shown to function as a
regulator of the T-cell immune response by its effects on
T-cell proliferation [16]. Notably, Sema7A has been dem-
onstrated to have a clear effect on the migration processes
of osteoblasts and osteoclasts in bone remodeling and a
distinct role in tumor angiogenesis [17, 18]. Neovasculari-
zation, immunologic abnormality, and bone erosion all
have crucial roles in the progression of RA [19, 20], sug-
gesting that Sema7A may aggravate RA. However, the
pathologic significance of Sema7A in RA remains unclear.
On the basis of these observations, we analyzed the role
of secreted Sema7A in the modulation of cellular im-
munological functions and the pathogenesis of RA. Our
findings identified that Sema7A is an attractive activator
of T cells and monocytes in the synovial lesions of patients
with RA. Furthermore, the elevated levels of soluble sema-
phorin 7A (sSema7A) were proteolytically shed from the
cell surface, and the resultant sSema7A contributed to in-
flammation, suggesting that an inflammatory activation
loop exists in RA synovium. Moreover, we demonstrate
that Sema7A mediates its intracellular effects via interac-
tions with β1-integrins and the activation of focal adhe-
sion kinase (FAK). The inhibition of Sema7A attenuated
the development of collagen-induced arthritis (CIA). In
the present study, we explored the key role of Sema7A in
immunoregulation, and we provide experimental data val-
idating the therapeutic potential of Sema7A in RA.
Methods
Subjects
Blood samples were collected from 55 patients with RA
and 12 with osteoarthritis (OA). Blood samples were also
obtained from healthy donors. Synovial tissue and fluid
samples were collected during knee joint replacement
surgery from patients with RA (n =15) and patients with
OA (n = 10). These patients presented with high levels of
C-reactive protein (CRP) (29–138 mg/L, mean 66 mg/L)
and rheumatoid factor (RF) (63–432 U/ml, mean 214.8 U/
ml). Thirty-three of the 55 patients with RA had a Disease
Activity Score in 28 joints (DAS28) ≥3.2 [21]. All patients
with RA fulfilled the revised American College of
Rheumatology criteria [22]. All cases of OA were classified
as grade IV on the basis of clinical and radiological criteria
according to the Kellgren-Lawrence grading scale [23]. All
of the patients provided written informed consent to par-
ticipate in this study. The ethics committee of Nanjing
Medical University approved this study.
Cell isolation and culture
Isolation of human peripheral blood mononuclear cells
(PBMCs) was performed as described previously [20].
PBMCs were analyzed on a fluorescence-activated cell-
sorting (FACS) flow cytometer (BD Biosciences, San
Jose, CA, USA) using FlowJo software (FlowJo, Ashland,
OR, USA). CD4+ T cells and CD14+ monocytes were
purified from PBMCs by incubating cells with anti-CD4
and anti-CD14 monoclonal antibody (mAb). The follow-
ing antibodies were used: anti-human CD4 phycoerythrin
(PE) (BD Biosciences) and anti-human CD14 PE (BD Bio-
sciences). The purity of isolated CD4+ T cells and CD14+
monocytes was >95% in all experiments. The cell surface
expression of Sema7A in peripheral blood CD4+ and
CD14+ cells was detected by flow cytometric analyses
using PE-conjugated anti-human Sema7A (BioLegend,
San Diego, CA, USA). THP-1 cells were cultured in RPMI
1640 medium supplemented with 10% heat-inactivated
FBS and penicillin-streptomycin.
Synovial macrophage isolation
After synovial tissues were digested, the samples were
filtered using a cell strainer (BioLegend). The adherent
synovial cells were harvested. After overnight culture, pri-
mary synovial cells were employed for synovial macro-
phage isolation using a magnetic-activated cell sorting
separation column system (Miltenyi Biotec, Bergisch
Gladbach, Germany) as previously described [23]. Adher-
ent cells were incubated with CD14-labeled microbeads
for 30 minutes at 4 °C, and this mixture was then applied
to a magnetic column. The positive fraction (CD14+) was
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used as the synovial macrophage. CD14+ cells were
incubated for 24 h with 1 mg/ml of IL-6 and 0.1 mg/ml of
TNF-α (PeproTech, Rocky Hill, NJ, USA) in Dulbecco’s
modified Eagle’s medium containing 10% fetal calf serum.
The concentrations of a disintegrin and metalloprotease
17 (ADAM17) and Sema7A in the culture supernatants
were also measured by enzyme-linked immunosorbent
assay (ELISA).
Cytokine production assay
For the analysis of cytokine secretions, freshly isolated
CD4+ T and CD14+ cells (2 × 105) from patients with RA
were incubated in the presence of Sema7A-Fc fusion
protein (10 ng/ml) at the indicated concentrations for
48 h. Cells cultured in the absence of Sema7A (negative
control [NC]) or in the presence of heat-denatured
Sema7A (DSema7A) were used as an NC or an add-
itional control. DSema7A was produced by incubating
Sema7A at 95 °C for 20 minutes. Supernatants from T-
cell cultures were then collected and analyzed for cyto-
kine secretion. The concentrations of human TNF-α, IL-
6, interferon-γ (IFN-γ), IL-22, and IL-17 in the culture
supernatants were determined using ELISA kits for each
cytokine (R&D Systems, Minneapolis, MN, USA). For
the blocking experiments, the CD14+ cells were cocul-
tured with 10 ng/ml of Sema7A and 10 ng/ml of anti-
Sema7A antibody, anti-β1-integrin antibody, or anti-
plexin C1 antibody (BioLegend), or with immunoglobu-
lin G (IgG) as a control, for 36 h. The levels of IL-6 and
TNF-α in the supernatants were evaluated by ELISA.
sSema7A levels in patients’ serum and synovial fluid
samples from and in the cell culture supernatants were
detected using an ELISA kit (R&D Systems). The levels
of ADAM17 in the serum and synovial fluid samples
were also determined using an ELISA kit (MyBioSource,
San Diego, CA, USA).
Human Sema7A-Fc fusion proteins were produced as
previously described [11, 16], and recombinant human
IgG1-Fc (R&D Systems) was used as a control. Naturally
cleaved sSema7A was affinity-purified, performed as pre-
viously described [16].
Reverse transcription-quantitative polymerase chain
reaction
PBMCs or CD4+ or CD14+ cells (2 × 105) were isolated
using a FACS flow cytometer (BD Biosciences). The total
RNA was extracted from the cells using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. The complementary DNA was
synthesized using SuperScript III reverse transcriptase
(Invitrogen) according to the manufacturer’s protocol. A
LightCycler (Roche, Basel, Switzerland) and a SYBR reverse
transcription-polymerase chain reaction (RT-PCR) kit
(Toyobo, Osaka, Japan) were used for the quantitative real-
time RT-PCR analysis in accordance with the manufac-
turer’s instructions. The sequences of the primer sets for
Sema7A, β1-integrin, and plexin C1, as well as the target
sites on the messenger RNA (mRNA) and the PCR product
sizes, are shown in Table 1. β-actin was used to normalize
the samples. The relative quantification of each gene was
determined using LightCycler 480SW software (Roche).
Western blot analysis
Cultured CD4+ T cells from healthy control subjects were
stimulated with Sema7A for 3 h. Unstimulated cells or T
cells treated with DSema7A were used as controls. The
cells were washed twice with ice-cold PBS and lysed in lysis
buffer consisting of 25 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS, and cOmplete Mini
protease inhibitor cocktail (Roche). For phosphorylation-
specific immunoblot analysis, phosphatase inhibitors
(10 mM NaF, 12.5 mM β-glycerophosphate, and 1 mM
Na3VO4) were added to the lysis buffer. Whole-cell lysates
were subjected to SDS-PAGE under reducing conditions.
Immunoblotting was performed using antibodies specific
to retinoic acid receptor-related orphan nuclear receptor γt
(RORγt; BioLegend) and T-bet (BD Biosciences).
The CD14+ cells from patients with RA were stimulated
with 10 ng/ml of recombinant Sema7A or DSema7A for
15 minutes. CD14+ cells stimulated with DSema7A were
used as negative controls. The activation of FAK was eval-
uated by immunoblotting using antibodies specific to FAK
(Santa Cruz Biotechnology, Dallas, TX, USA), phospho-
FAK (Tyr397) (BD Biosciences), and glyceraldehyde 3-
phosphate dehydrogenase (Abcam, Cambridge, UK).
Shedding of sSema7A
The THP-1 cell line and CD14+ cells from patients with
RA were cultured in RPMI 1640 medium containing
1 μM of BMS-561392 (Bristol-Myers Squibb, New York,
NY, USA) or 100 μM of GM6001 (Calbiochem, San Diego,
CA, USA) for 7 minutes at room temperature before the
THP-1 and CD14+ cells were incubated for 12 h with
0.1 mg/ml of TNF-α and 1.0 mg/ml of IL-6. sSema7A
concentrations were measured by Western blotting.
Table 1 Primers for human semaphorin 7A, β1-integrin, and
plexin C1
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Small interfering RNA experiments
HEK293T cells were transduced with a pcDNA3.1 vector
containing the Sema7A sequence. HEK293T cells stably ex-
pressing Sema7A (HEK293T_Sema7A) were infected with
a lentiviral vector containing short-hairpin RNA (shRNA)
specific for ADAM17 (5′-GCTTGATTCTTTGCTCTCA-
3′) or a nonspecific shRNA. The preparation of the lenti-
viral vector and cell transduction were performed according
to previously described protocols [24]. ADAM17 mRNA
expression was assayed by RT-PCR 48 h after cell trans-
duction. sSema7A levels in the cell supernatant were deter-
mined by Western blot analysis 5 days after the silencing of
ADAM-17 expression.
Induction and assessment of CIA
The CIA model was induced in the mice as previously de-
scribed [25, 26]. Briefly, DBA/1 mice were obtained from
the Shanghai Animal Center (Shanghai, China). Eight-
week-old DBA/1 mice were given intradermal injections
of 100 μg/mouse of bovine collagen type II (CII) (Cosmo
Bio, Tokyo, Japan) emulsified in complete Freund’s adju-
vant containing 250 μg/mouse of heat-killed Mycobacter-
ium tuberculosis H37Ra (BD Biosciences). Twenty-one
days after immunization, the mice were given a booster
injection at the base of the tail with 100 μg/mouse of
bovine CII. Mice with CIA were given intraperitoneal in-
jections of 12 μg/mouse of anti-Sema7A antibody
(AF1835, goat IgG; R&D Systems) (n = 8), 9 μg/mouse of
anti-Sema7A antibody (n = 8), or isotype control anti-
bodies (R&D Systems) on days 1, 10, 20, 30, and 40.
Serum was collected on day 50. Serum levels of TNF-α,
IL-6, and IL-17 were evaluated by ELISA (R&D Systems).
To evaluate the incidence and severity of arthritis,
arthritis was scored by two calibrated examiners via a visual
assessment scoring system using a scale of 0–4 per limb as
previously described [25, 27]. The severity scores were
defined as follows: 0 = no evidence of erythema and swell-
ing; 1 = erythema and mild swelling confined to the midfoot
(tarsals) or ankle joint; 2 = erythema and mild swelling
extending from the ankle to the foot; 3 = erythema and
moderate swelling extending from the ankle to the metatar-
sal joints; and 4 = erythema and severe swelling encom-
passing the ankle, foot, and digits. The paws of mice
stimulated with anti-Sema7A antibody (n = 8), the control
antibody (n = 8), or no antibody (n = 6) were fixed and
decalcified. Histologic scoring and the histomorphometric
analysis of the paws were performed by an investigator
blinded to treatment status.
Statistical analysis
Statistical analysis of the data was performed using SPSS
version 16 software (SPSS, Chicago, IL, USA). Nonpara-
metric Mann-Whitney U tests were used to compare
two groups, and comparisons between three groups were
performed using the Kruskal-Wallis test followed by the
Mann-Whitney U test. P values less than or equal to
0.05 were considered significant. Correlations between
clinical parameters and Sema7A were determined using
Spearman’s correlation. The data are presented as SDs.
Results
Significantly increased levels of sSema7A in patients with
RA and correlation with disease activity
Several members of the semaphorin family have been
characterized with respect to their function in immunity.
To explore the pathologic role of Sema7A in RA, we
first detected the serum levels of Sema7A in patients
with immunologic and joint-destructive diseases. The
serum levels of secreted Sema7A were determined by
ELISA in a large cohort of patients with RA (n = 55) and
patients with OA (n = 12) in comparison with healthy in-
dividuals (n = 60).
Interestingly, the levels of serum sSema7A were remark-
ably increased in patients with RA compared with healthy
subjects (mean ± SD 13.6 ± 3.7 ng/ml versus 5.7 ± 2.8 ng/
ml; P < 0.01). In contrast, serum sSema7A levels were not
elevated in patients with OA. We next performed ELISA to
determine the Sema7A levels in the synovial fluid of
patients with RA and OA. A significantly increased level of
Sema7A was detected in fluid from patients with RA (12.3
± 6.5 ng/ml) compared with that from patients with OA
(3.1 ± 2.4 ng/ml) (P < 0.01) (Fig. 1a). To investigate the clin-
ical significance of sSema7A, we analyzed the correlations
between clinical features and levels of serum sSema7A.
Importantly, there was a positive correlation between
sSema7A and disease activity markers such as the DAS28
(r2 = 0.817, P < 0.01), the CRP level (r2 = 0.760, P < 0.01),
and the RF titer (r2 = 0.621, P < 0.01) (Fig. 1b). In contrast,
no relationship between serum sSema7A levels and disease
duration, age, or sex were observed (data not shown).
Serum levels of sSema7A were examined before and
6 months after the beginning of biologic disease-modifying
antirheumatic drug (DMARD) therapy (31 patients were
treated with TNF inhibitors). A significant reduction in
serum sSema7A levels after biologic DMARD treatment
was observed (mean ± SD 12.6 ± 4.3 ng/ml versus 6.7 ±
2.6 ng/ml; P < 0.01) in patients who were good responders
according to the European League Against Rheumatism re-
sponse criteria [28] (Fig. 1c), suggesting the involvement of
Sema7A in determining the clinical status of RA.
Expression of Sema7A and its upregulation of secretion
of proinflammatory cytokines in T cells and monocytes/
macrophages
Studies suggest that members of the semaphoring family are
important players during the immune response because they
regulate interactions between T cells and antigen-presenting
cells during the primary immune response [29, 30]. To
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explore whether Sema7A expression by T cells and mono-
cytes differed in patients with RA compared with control
subjects, we isolated CD4+ cells and CD14+ cells and
performed flow cytometry. Notably, cell surface Sema7A
expression was downregulated on all cells from patients with
RA (Fig. 2a). Furthermore, cell surface Sema7A was
expressed richly on CD14+ and CD4+ cells in healthy indi-
viduals. In contrast, the expression of the Sema7A transcript
was not reduced in CD4+ and CD14+ cells from patients
with RA compared with healthy donors (Fig. 2b), suggesting
that the reduction in cell surface Sema7A was due to shed-
ding of Sema7A from the cell surface.
Next, we assessed the effect of Sema7A on the cytokine
production of PBMCs from healthy subjects. Culture
supernatants were collected after 48 h of incubation and
analyzed for secreted cytokines by ELISA. The secretions
of IL-6, TNF-α, and IL-17 were significantly increased
after stimulation with Sema7A (Fig. 2c). Notably, the in
vitro stimulation of CD4+ cells with Sema7A led to a sig-
nificant increase in the secretion of Th17/Tc17 cytokines,
including IL-17, IFN-γ, and IL-22, compared with un-
stimulated cells or cells stimulated with DSema7A
(Fig. 2d). These data indicate that sSema7A can strongly
increase the production of inflammatory cytokines, in par-
ticular Th17/Tc17 and Th1/Tc1, by T cells in vitro.
Previous studies have shown that Sema7A is a potent
stimulator of monocytes and induces the production of
proinflammatory cytokines. Monocytes and macrophages
are critical effector cells of the inflammatory immune
response in RA [30, 31]. Next, to examine whether
Sema7A serves a crucial role by affecting inflammatory
immune functions in RA, we assessed the effect of
sSema7A on monocyte IL-6 and TNF-α production
among patients with RA in vitro. Treatment with cleaved
sSema7A or sSema7A-Fc increased the production of
TNF-α and IL-6 by CD14+ monocytes/macrophages.
Moreover, the anti-Sema7A antibody suppressed IL-6 and
TNF-α secretion stimulated by sSema7A (Fig. 2e). These
results showed that sSema7A can induce inflammatory
cytokine production by monocytes/macrophages, suggest-
ing that Sema7A might have a pathogenic role in RA.
Role of Sema7A in the expression of T-bet and RORγt by
T cells
Increasing data indicate that the latter types of CD4+ cells,
such as Th1 and Th17 cells, are key players in the devel-
opment of RA [6, 31, 32]. Th1 cells are characterized by
their expression of the transcription factor T-bet [33].
Th17 cells are a subgroup of helper T cells with the cap-
ability to produce high levels of IL-17, which is their main
characteristic, along with the expression of the transcrip-
tion factor RORγt [34]. As mentioned above, T cells stim-
ulated with Sema7A induced the production of cytokines
that were relevant to Th1/Tc1 and Th17/Tc17 subclasses.
Next, we evaluated the effect of Sema7A stimulation on
RORγt and T-bet expression in T cells. After the induction
of CD4+ cells by Sema7A, we found that Sema7A caused
a significant elevation in the expression of both RORγt
Fig. 1 Levels of soluble semaphorin 7A (sSema7A) and correlation with markers of rheumatoid arthritis (RA) disease activity. a sSema7A levels in
serum and synovial fluid samples from patients with RA and patients with osteoarthritis (OA). b Serum sSema7A levels before and after biologic
disease-modifying antirheumatic drug treatment in good responders according to the European League Against Rheumatism response criteria.
Values in a and b are mean ± SD. **P < 0.01; ***P < 0.001. N.S Not significant. c Correlation between serum sSema7A levels with rheumatoid factor
(RF) titer, Disease Activity Score in 28 joints (DAS28), and C-reactive protein (CRP) level (n = 31 samples)
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and T-bet compared with unstimulated cells or cells
stimulated with DSema7A (Fig. 3a and b). These data sug-
gested that Sema7A induced CD4+ cells to differentiate
into Tc1/Tc17 and Th1/Th17 subclasses, respectively.
Effect of Sema7A receptors on cytokine production
The effects of Sema7A are believed to be mediated via two
receptors: plexin C1 and the β1-integrin subunit [35, 36].
To investigate whether β1-integrin and/or plexin C1 is
implicated in the stimulatory effect of Sema7A observed in
monocytes, we first evaluated the mRNA levels of β1-
integrin and plexin C1 by quantitative RT-PCR in CD14+
monocytes derived from patients with RA and healthy sub-
jects. We found that the mRNA levels of β1-integrin and
plexin C1 were significantly upregulated in patients with
RA compared with healthy subjects. Interestingly, the
mRNA levels of β1-integrin were significantly higher than
the levels of plexin C1 in RA CD14+ monocytes (Fig. 4a).
Next, blocking assays were performed with anti-plexin
C1 or anti-β1-integrin antibody. The monocytes were
stimulated with Sema7A or anti-plexin C1 or anti-β1-
integrin antibody, and cytokine secretion was analyzed.
Sema7A-induced cytokine secretion was significantly
inhibited in the presence of the anti-β1-integrin antibody
compared with control cells stimulated with Sema7A in
the absence of the anti-β1-integrin antibody. Notably,
cytokine secretion by Sema7A was barely inhibited in the
presence of the anti-plexin C1 antibody compared with
the presence of the anti-β1-integrin antibody (Fig. 4b).
These data indicate that Sema7A may induce cytokine se-
cretion from CD14+ cells via interactions with β1-integrin.
Fig. 2 Semaphorin 7A (Sema7A) expression, and inflammatory
cytokine synthesis induced by Sema7A in primary human cells. a
Cell surface expression of Sema7A in peripheral blood CD4+ and
CD14+ cells and peripheral blood mononuclear cells (PBMCs) from
patients with rheumatoid arthritis (RA) and healthy volunteer donors.
Results shown are representative of findings from nine patients with
RA and eight healthy volunteer donors. b Expression of messenger
RNA (mRNA) for Sema7A in peripheral blood CD4+ and CD14+ cells.
Results shown are from nine patients with RA and eight healthy
individuals. N.S. Not significant. c Cytokine production by PBMCs from
healthy donors (n = 6 percytokine) after treatment with or without
Sema7A (10 ng/ml) for 24 h. Supernatants were analyzed for
expression of IL-17, TNF-α, and IL-6 by enzyme-linked immunosorbent
assay. Results are shown as the mean of triplicate values ± SD from one
of three representative experiments. *P<0.05 versus unstimulated con-
trols. d Interferon-γ (IFN-γ), IL-17, and IL-22 synthesis by primary human
CD4+ T cells from patients with RA after treatment with either Sema7A
or heat-denatured Sema7A (DSema7A) (both at 10 ng/ml) for 24 h.
Data are shown as the mean of triplicate values ± SD as compared with
DSema7A (10 ng/ml) or unstimulated CD4+ T cells. **P < 0.01. e Tumor
necrosis factor-α (TNF-α) and interleukin-6 (IL-6) production by primary
human CD14+ monocytes from patients with RA after stimulation with
naturally cleaved soluble Sema7A (sSema7A) for 48 h with or without
anti-Sema7A antibody. Results shown are representative of three
independent experiments
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Although it has been proposed that plexin C1 is a Sema7A
receptor, the effect of Sema7A on monocytes is independ-
ent of plexin C1. These observations further reinforce that
β1-integrin may be the major receptor for Sema7A in
monocytes from patients with RA.
Sema7A signaling through β1-integrin activates FAK
Sema7A has been reported to promote axon outgrowth
through the activation of non-receptor tyrosine kinase FAK
during the embryonic development of neuronal progenitor
cells [37]. FAK is a pivotal signal transducer downstream of
integrins [38, 39]. Moreover, it is known that signaling
through integrins such as β1-integrin activates FAK [39].
To determine whether Sema7A elicits integrin-dependent
signaling responses in CD14+ monocytes from patients with
RA, we measured the level of FAK phosphorylation by
performing immunoblot analysis in CD14+ monocytes and
THP-1 cells stimulated with Sema7A or DSema7A for 1 h.
As shown in Fig. 4c, the phosphorylation of FAK was
detected after stimulation with Sema7A. In contrast,
DSema7A was used as a negative control and did not cause
FAK phosphorylation. These data indicate the role of
integrin-associated signal transduction machinery in propa-
gating Sema7A signals.
Cleavage of Sema7A from cell surface
Previous studies established that Sema7A as a transmem-
brane protein can produce a soluble form by shedding
from the cell surface [40]. The mechanism by which
Sema7A is cleaved from the cell surface is not well under-
stood. It is now clear that metalloproteinases are involved
in the ectodomain shedding of many important cell
surface proteins [41]. Previous studies have established
that the cleavage of GPIbα and Sema4D is mediated by
ADAM17 [42, 43]. Sema7A is a GPI-anchored member of
the semaphorin family [44]. Thus, we determined whether
ADAM17 was implicated in the shedding of Sema7A from
the monocyte membrane. We incubated Sema7A-
expressing cells (THP-1 cells and CD14+ cells) with BMS-
561392, a potent and selective inhibitor of ADAM17, or
GM6001, a general inhibitor of metalloproteinases [45].
GM6001 inhibits Sema7A cleavage by 72% when CD14+
cells are activated by IL-6 and TNF-α. The corresponding
proportion for BMS-561392 is 65% (Fig. 5a). Thus, the
results validated the detection of sSema7A in the shedding
analysis and suggest that ADAM17 is probably the
shedddase. Consistent with this finding, we measured the
enhanced levels of ADAM17 in the serum and synovial
fluid of patients with RA (Fig. 5b and c), and we found
that TNF-α and IL-6 stimulated the secretion of ADAM17
by monocytes/macrophages detected in the patients with
RA in this study (Fig. 5d).
To further investigate the role of ADAM17 in the
shedding of Sema7A, we established stable HEK293T
cell lines overexpressing ADAM17 or Sema7A. sSe-
ma7A was detected in the cell culture supernatants
with nonspecific shRNA expression. ADAM17 ex-
pression was silenced using a vector encoding for
ADAM17-specific shRNA in HEK293T cell lines
overexpressing ADAM17 or Sema7A. ADAM17 shRNA
resulted in a significant decrease in the levels of
sSema7A in the cell culture supernatant of HEK293T
cells overexpressing ADAM17 or Sema7A (Fig. 5e).
Thus, these results validate the detection of Sema7A in
the shedding analysis and suggest that ADAM17 is
probably shed in patients with RA.
Fig. 3 Semaphorin 7A (Sema7A) enhances expression of retinoic acid receptor-related orphan nuclear receptor γt (RORγt) and T-bet transcription
factor in CD4+ T cells from healthy donors. Freshly isolated T cells (CD4+) were stimulated with 10 ng/ml of Sema7A or heat-denatured Sema7A
(DSema7A) for 2 h. The expression of (a) T-bet and (b) RORγt was detected by immunoblotting. Bars show the mean ± SD of three independent
experiments. **P < 0.01 versus unstimulated control or DSema7A. NC Negative control cells cultured in the absence of Sema7A
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Blocking of Sema7A attenuates CIA
Next, we investigated whether the blocking of Sema7A
using an anti-Sema7A antibody has the ability to prevent
and treat the development of CIA in DBA/1 mice, a surro-
gate model of human RA. For the CIA treatment studies,
mice with established clinical arthritis (an average score of
4) were randomized and given an injection with anti-
Sema7A antibody or a control antibody. In the prevention
model, blocking Sema7A demonstrated that treatment
with anti-Sema7A antibody significantly reduced the
development of CIA. Indeed, we observed that the arth-
ritis scores and paw swelling in mice treated with anti-
Sema7A antibody were significantly reduced compared
with those in control mice (Fig. 6b), and the reduction in
the arthritis scores was attenuated in mice treated with
half a dose of the antibody. Histologic examination
revealed that blocking Sema7A in mice with CIA also
reduced disease severity and was accompanied by reduced
bone erosion, synovial hyperplasia, and inflammatory
infiltration into the joint compartment (Fig. 6a). The
histologic scores in the joints of mice treated with anti-Se-
ma7A antibody were significantly decreased (Fig. 6d).
Moreover, serum TNF-α, IL-17, and IL-6 levels on day 50
were significantly decreased in mice treated with anti-
Sema7A antibody (Fig. 6c).
Discussion
Although Sema7A has been involved in immunologic dis-
orders, there are few reports regarding its expression and
immunological function in RA. The present study is the
first, to our knowledge, to show that sSema7A is signifi-
cantly increased in the synovial fluid and serum of patients
with the inflammatory autoimmune disease RA compared
with OA. Furthermore, we demonstrate that the levels of
sSema7A strongly stimulated inflammatory T-cell and
monocyte/macrophage responses in vitro. Second, we
demonstrated that Sema7A is involved in the inflammatory
response in RA and is also correlated with disease activity.
Fig. 4 Blocking β1-integrin abrogates semaphorin 7A (Sema7A)-induced cytokine production from CD14+ cells in rheumatoid arthritis (RA). a Expres-
sion of messenger RNA (mRNA) for Sema7A receptors (plexin C1 and β1-integrin) in peripheral blood CD14+ cells from patients with RA and from
healthy individuals. Results shown are from 14 patients with RA and 12 healthy individuals. Values in a–c are mean ± SEM. *P < 0.05, **P < 0.01. b RA
CD14+ cells were incubated with the anti-β1-integrin monoclonal antibody (mAb) or anti-plexin C1 mAb in the presence of soluble Sema7A. After 48-
h cultivation, supernatants were collected for expression of TNF-α and IL-6 by enzyme-linked immunosorbent assay. Results shown are representative
of findings from eight patients with RA and six healthy volunteer donors. c Phosphorylation of focal adhesion kinase (FAK) in THP-1 and CD14+ cells
upon exposure to Sema7A. Isolated CD14+ cells were exposed to 10 ng/ml of recombinant Sema7A. Cells exposed to heat-inactivated Sema7A (DSe-
ma7A) were used as negative controls. Phosphorylation of FAK was evaluated by immunoblot analysis. Activation of FAK was detected after 3 min of in-
cubation with Sema7A. Results shown are representative of three independent experiments. NS Not significant
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We assessed the relationship between serum sSema7A
levels and known clinical and biologic markers usually
used in the diagnosis and prediction of RA. Interest-
ingly, a significant correlation between serum sSe-
ma7A levels and the levels of DAS28, CRP, and RF in
patients with RA was observed. Furthermore, success-
ful treatment with biologic DMARDs in patients with
RA decreased serum sSema7A levels. In general, these
data indicate that sSema7A is a potentially useful bio-
marker for RA disease activity, further supporting its
role in the progression of RA.
An increasing amount of data shows that Sema7A is
an important player during the immune response be-
cause it regulates the interactions between T cells and
monocytes during the primary immune response [29].
The immunogenetics of RA suggest the key role for ab-
normal pathways of T-cell and monocyte activation in
the perpetuation of disease [46]. Thus, we decided to in-
vestigate the role of Sema7A in RA. Recombinant sSe-
ma7A was performed to evaluate its effects on T cells
and monocytes. Our data reveal that sSema7A regulated
cytokine secretion by T cells and monocytes. An analysis
of T-cell and monocyte cytokine production showed that
stimulation with Sema7A led to strongly enhanced pro-
duction of proinflammatory cytokines, such as TNF-α
and IL-6. Interestingly, it has been shown that these cy-
tokines play central roles in RA disease progression and
recruit inflammatory cells to erode the joints of patients
with RA [46]. It thus appears that Sema7A is involved in
the pathogenesis of RA.
Fig. 5 A disintegrin and metalloprotease 17 (ADAM17) contributes to the shedding of semaphorin 7A (Sema7A). a Shedding of Sema7A is
inhibited by metalloproteinase inhibitors. Western blots show Sema7A in the supernatant of THP-1 and CD14+ cells stimulated with tumor necro-
sis factor-α (TNF-α) and interleukin-6 (IL-6) in the presence of the metalloprotease inhibitor GM6001 or the ADAM17-selective inhibitor BMS-
561392 (BMS). Results shown are representative of three independent experiments. b Elevated serum ADAM17 levels in 26 patients with rheuma-
toid arthritis (RA) and 23 healthy donors. d Synovial fluid levels of ADAM17 in 11 patients with RA and 8 patients with osteoarthritis (OA). c Syn-
ovial fluid levels of ADAM17 in 11 patients with RA and 8 patients with osteoarthritis (OA). d ADAM17 protein levels in primary cultures of TNF-α-
and IL-6-stimulated synovial macrophages from patients with RA. Data were compiled from three independent experiments. Values are mean ±
SEM. **P < 0.01. e HEK293T cells stably expressing transmembrane Sema7A (HEK293T_Sema7A) were transduced with vectors encoding an
ADAM17-specific short-hairpin RNA (shADAM17) or a nonspecific short-hairpin RNA (shNS). Levels of secreted Sema7A in the cell culture super-
natant were analyzed by Western blotting. Results shown are representative of three independent experiments
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In this study, we also demonstrated that the produc-
tion of the inflammatory cytokines IFN-γ (formally at-
tributed to Th1 response) and IL-17 (the well-known
Th17-derived cytokine) was significantly increased in T-
cell culture supernatant induced by sSema7A. These re-
sults were also confirmed by the significant upregulation
of the expression of transcription factor T-bet and
RORγt in CD4+ T cells following stimulation with
Sema7A. A previous report suggested that T-bet and
RORγt promote the differentiation of T cells into Th1/
Tc1 and Th17/Tc17 subsets, respectively [47]. Recently,
it has become clear that both Th1 and Th17 cytokines
are key players in the development of RA [48]. Further-
more, we observed that Sema7A significantly enhanced
the production of Th17/Tc17 cytokines, including IFN-γ,
IL-22, and IL-17, in comparison with cells treated with
DSema7A. Collectively, these findings demonstrate that
Sema7A can strongly elevate the production of inflam-
matory cytokines, particularly Th17/Tc17 and Th1/Tc1,
which is strongly similar to the characteristic cytokine
profile of patients with RA displayed by T cells in vitro.
To further determine the possible mechanism of ac-
tion of Sema7A, we explored intracellular signal trans-
duction pathways. Plexin C1 and β1-integrin molecules
were shown to serve as Sema7A receptors. To determine
whether both receptors may play roles in the stimulatory
effect of Sema7A observed in T cells and monocytes, we
evaluated the plexin C1 and β1-integrin mRNA levels in
T cells and monocytes isolated from patients with RA
and healthy subjects. Both receptor mRNA levels were
significantly upregulated in patients with RA compared
with healthy subjects. Next, we tested whether Sema7A
mediates its intracellular effects via interactions with
plexin C1 and β1-integrin. Blocking assays were per-
formed in CD14+ cells with anti-β1-integrin antibody or
anti-plexin C1 antibody in the presence or absence of
Sema7A. Interestingly, Sema7A-induced cytokine secre-
tion was attenuated by the blockage of β1-integrin but not
plexin C1 in CD14+ cells, suggesting that β1-integrin is a
binding partner for Sema7A in monocytes. As previously
reported, our results showed that the Sema7A-induced
cytokine secretion from monocytes was also significantly
inhibited by an anti-β1-integrin mAb alone. In the present
study, we observed that Sema7A induces the activation of
FAK in CD14+ cells. These results suggest that Sema7A
signaling occurs through the engagement of β1-integrin in
monocytes, given that signaling through integrins com-
monly leads to FAK activation.
In the present study, the expression of Sema7A mRNA
was stable in CD4+ cells, and CD14+ cells. However, the ex-
pression levels of Sema7A at the cell surface were actually
decreased in T cells and monocytes from the peripheral
Fig. 6 Blocking of semaphorin 7A (Sema7A) attenuates severity of collagen-induced arthritis (CIA) in mice. a Histological examination of a mouse
ankle joint on day 50 after treatment with anti-Sema7A antibody. Sections were stained with hematoxylin and eosin. Original magnification × 400.
b and c Average arthritis scores and paw swelling of mice with CIA. Mice (n = 8 per group) were immunized with collagen type II, randomized,
and, at onset of disease (clinical score of 4), anti-Sema7A or control antibody (Ab) (12 μg/mouse) was administered intraperitoneally on days 1,
10, 20, 30, and 40 (n = 8 mice per group). Data are representative of three independent experiments. d Average histologic scores of paw sections
on day 50 (n = 8 mice per group). e Serum samples were collected for expression of tumor necrosis factor-α (TNF-α), interleukin-17 (IL-17), and
IL-6 by enzyme-linked immunosorbent assay on day 50 (n = 8 mice per group). Data were compiled from three independent experiments.
Values are mean ± SEM. **P < 0.01
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blood of patients with RA. Thus, we speculated that the
relative decrease in cellular Sema7A levels may be attribut-
able to the shedding of Sema7A from the cell surface. In
support of this notion, other studies established that the
transmembrane semaphorins can be proteolytically cleaved
to produce soluble proteins, and the proteinase responsible
for cleavage has been identified: It is a member of the
ADAM family [49]. It has been shown that the cleavage of
GPIbα is mediated by ADAM17. On the basis of our ana-
lysis of the results described above, we speculated that
Sema7A, a GPI-anchored member of the semaphorin
family, might be one of the proteins cleaved by ADAM17.
Consistent with this finding, our results validated the
detection of Sema7A in the shedding analysis and suggest
that ADAM17 was probably the sheddase. In addition, our
results indicated that sSema7A induced TNF-α and IL-6
production and that both TNF-α and IL-6 induced the
production of ADAM17. The levels of ADAM17 were
increased in synovial fluid and serum from patients with
RA. Hence, we propose that Sema7A functions as an auto-
crine stimulator of the IL-6/TNF-α inflammatory axis in
patients with RA.
To further confirm that Sema7A has a distinct role in
the pathogenesis of RA in vivo, we introduced anti-
Sema7A antibody into a T-cell- and monocyte-dependent
animal model of RA, namely, CIA. Blocking Sema7A in
CIA exerted favorable therapeutic effects and achieved a
dramatic arrest in disease progression, as confirmed by
the clinical, histopathological, and immunological mani-
festations of arthritis. These observations extend our
findings demonstrating that Sema7A has a distinct role in
regulating inflammatory responses in vivo, suggesting that
Sema7A might be a possible therapeutic target for RA.
Furthermore, sSema7A has been reported to promote
angiogenesis. Angiogenesis is thought to have an import-
ant role in the progression of arthritic lesions in RA.
Therefore, it is attractive to speculate that Sema7A may
be further involved in the pathogenesis of RA by promot-
ing the angiogenesis of joint tissue, which would recruit
the inflammatory cells into the synovium.
Conclusions
Taken together, our results show that the levels of secreted
Sema7A were significantly high in the serum and synovial
fluid of patients with RA and that Sema7A is a promising
biomarker for RA disease. The crucial roles of Sema7A in
the pathogenesis of RA suggest that Sema7A is a potential
therapeutic target for RA. Therefore, our results provide a
further rationale for prospective clinical studies designed
to evaluate whether Sema7A provides effective therapeutic
activities in RA and other autoimmune diseases.
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